Viracta Therapeutics (FRA:RYI) Institutional Ownership : 5.94% (As of Jun. 19, 2024)

View and export this data going back to 2021. Start your Free Trial

What is Viracta Therapeutics Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Viracta Therapeutics's institutional ownership is 5.94%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Viracta Therapeutics's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Viracta Therapeutics's Float Percentage Of Total Shares Outstanding is 78.57%.

Viracta Therapeutics Institutional Ownership Historical Data

The historical data trend for Viracta Therapeutics's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Viracta Therapeutics Institutional Ownership Chart

Viracta Therapeutics Historical Data

The historical data trend for Viracta Therapeutics can be seen below:

	2023-08-31	2023-09-30	2023-10-31	2023-11-30	2023-12-31	2024-01-31	2024-02-29	2024-03-31	2024-04-30	2024-05-31
Institutional Ownership	9.06	8.35	6.24	6.18	5.97	5.97	5.97	5.95	5.95	5.94

Viracta Therapeutics Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

Viracta Therapeutics (FRA:RYI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Viracta Therapeutics Inc (FRA:RYI) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

VIRX:USA RYIS:Germany

Address

2533 South Coast Highway 101, Suite 210, Cardiff, CA, USA, 92007

Website

https://www.viracta.com

Viracta Therapeutics Inc is a precision oncology company, focused on the development of new medicines targeting virus-associated malignancies. The company is conducting three clinical trials for its combination product candidate as a potential therapy for the treatment of relapsed/refractory Epstein-Barr virus-positive lymphoma. Its lead product candidate is a combination product candidate consisting of nanatinostat, a potent and selective small molecule inhibitor of class I histone deacetylases (HDAC), and valganciclovir, an FDA-approved anti-viral drug used to treat and prevent disease caused by a virus called cytomegalovirus (CMV) in people who have received organ transplants.